The vaccines segment continues to draw the interest of participants beyond those firms with a traditional core presence, with new players largely building partnered capabilities around COVID-19 inoculations. Are these merely opportunistic forays or will the competitive landscape for vaccines stand altered more widely?
The vaccines space has traditionally been the preserve of a select group of companies but the pandemic has changed it all quite markedly, at least in India.
There’s been a stream of conventionally non-vaccine biopharma firms keen to tap into the segment, essentially via alliances for now....